Genscript Biotech grants significant share awards to executive, employees

Genscript Biotech Corporation announced on September 21, 2025, the grant of an aggregate of 774,960 share awards on September 19, 2025. These awards were issued under the company's 2019 RSU scheme, with the shares valued at the closing price of HK$17.06 per share on the grant date. The recipients include an executive director and other employees, with the grants satisfied by existing shares from previously lapsed RSUs, thus avoiding any dilutive effect on current shareholders.

Of the total, Dr. Li Zhu, an executive director, received 683,788 RSUs, representing approximately 0.0313% of the company’s issued share capital. The remaining 91,172 RSUs were granted to other employee grantees. The grants are subject to a vesting period of approximately three years, with annual vesting commencing from November 30, 2026, and full vesting by November 30, 2028. Vesting is conditional upon individual performance criteria, with a clawback mechanism also in place under specific circumstances.

The grants were approved by the independent non-executive directors and the remuneration committee. Post-grant, 205,403,242 underlying shares remain available for future grants under the scheme mandate limit, and 21,138,983 underlying shares under the service provider sublimit.